Streetbeat News

CDT

Conduit Pharmaceuticals Inc.

https://www.conduitpharma.com

Industry

Biotechnology

Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Open

0.14

Mkt cap

11M

Volume

575M

High

0.16

P/E Ratio

-0.47

52-wk high

7.83

Low

0.10

Div yield

N/A

52-wk low

0.08

Conduit Pharmaceuticals has received patent approval from the Japan Patent Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders. This development could enhance the company's market position and future revenue potential.

Portfolio Pulse from

November 21, 2024 | 12:45 pm

Conduit Pharmaceuticals has appointed Simon Fry, an experienced investment banking executive, to its Board of Directors. This move is expected to enhance the company's strategic development and capital market activities.

Portfolio Pulse from

November 19, 2024 | 9:45 pm

Conduit Pharmaceuticals (NASDAQ:CDT) has restructured a $2.65M loan with Nirland Limited, removing restrictive clauses, and secured $1.2M in new promissory notes. This enhances its balance sheet and liquidity, allowing more flexibility in future financing.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 8:48 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

In Thursday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

U.S. stocks rose with the Dow Jones gaining over 350 points. BlackRock reported strong Q3 results, boosting financial shares. Tesla shares fell 8% after its Cybercab unveiling. Other notable stock movements include Pacific Biosciences surging 30% and A.O. Smith dropping 7% after disappointing earnings.

Portfolio Pulse from Avi Kapoor

October 11, 2024 | 6:58 pm

U.S. stocks rose with the Dow Jones up 250 points. Wells Fargo shares gained over 5% after beating Q3 earnings expectations. Tesla shares dropped 8% following its Cybercab unveiling. Gold prices increased by 1.1%.

Portfolio Pulse from Avi Kapoor

October 11, 2024 | 4:49 pm

The Dow Jones index rose by 150 points, driven by strong earnings from JPMorgan Chase & Co. (JPM), which reported better-than-expected Q3 FY24 results. Financials led the market with a 1.3% increase, while consumer discretionary shares fell. Several stocks experienced significant price movements, including Top Wealth Group Holding Limited (TWG), ZenaTech Inc (ZENA), and Conduit Pharmaceuticals Inc (CDT), which saw substantial gains, while Inno Holdings Inc (INHD), Perspective Therapeutics Inc (CATX), and noco-noco Inc (NCNC) experienced declines.

Portfolio Pulse from Avi Kapoor

October 11, 2024 | 2:11 pm

Conduit Pharmaceuticals shares surged after AstraZeneca disclosed a 9.9% stake in the company.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:15 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included NewGenIvf Group (NIVF) with a 71.8% increase, Conduit Pharmaceuticals (CDT) up by 40.77%, and Kindly MD (KDLY) rising by 17.76%. On the losing side, Carmell (CTCX) fell by 12.4%, Jin Medical International (ZJYL) decreased by 8.74%, and LakeShore Biopharma (LSB) dropped by 8.14%.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.